单核细胞趋化蛋白-1及其受体在肝纤维化进程中的作用

郭悦承; 陆伦根

doi:10.3969/j.issn.1001-5256.2019.12.032

单核细胞趋化蛋白-1及其受体在肝纤维化进程中的作用

DOI: 10.3969/j.issn.1001-5256.2019.12.032

上海市第一人民医院消化科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1027
- HTML全文浏览量: 39
- PDF下载量: 229
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-11
- 出版日期: 2019-12-20

Role of monocyte chemoattractant protein 1 and its receptor in the progression of liver fibrosis

Department of Gastroenterology,Shanghai General Hospital

摘要

摘要: 肝纤维化是慢性肝损伤共有的可逆性病理改变,有进展为肝硬化、肝衰竭、门静脉高压的可能。近年来,多项研究指出,肝纤维化患者趋化因子谱发生显著变化,并且与肝纤维化的进展密切相关。单核细胞趋化蛋白-1（MCP-1）属于CC趋化因子家族,在肝纤维化进程中可发挥激活、募集、迁移炎症细胞的作用,并可能参与肝星状细胞（HSC）的激活、胰岛素抵抗（IR）的形成以及肝细胞癌（HCC）的进展。主要介绍了MCP-1及CC趋化因子受体（CCR） 2在肝纤维化发展中的可能作用以及相关疗法的最新进展。
- 单核细胞化学吸引蛋白质类 /
- 受体,CCR2 /
- 肝硬化 /
- 巨噬细胞
Abstract: Liver fibrosis is a common reversible pathological change in chronic liver injury and may progress to liver cirrhosis,liver failure,and portal hypertension. In recent years,several studies have shown a significant change in chemokine profiles in patients with liver fibrosis,which is closely associated with the progression of liver fibrosis. Monocyte chemoattractant protein 1( MCP-1) belongs to the family of CC chemokines and can induce the activation,recruitment,and migration of inflammatory cells during liver fibrosis. MCP-1 may be involved in the activation of hepatic stellate cells,the development of insulin resistance,and the progression to hepatocellular carcinoma. This article mainly reviews the potential role of MCP-1 and CC chemokine receptor in the progression of liver fibrosis and related therapies.
- monocyte chemoattractant protein /
- receptors,CCR2 /
- liver cirrhosis /
- macrophages

HTML全文

参考文献(33)

[1] TSOCHATZIS EA,BOSCH J,BURROUGHS AK. Liver cirrhosis[J]. Lancet,2014,383(9930):1749-1761.

[2] HOLT AP,HAUGHTON EL,LALOR PF,et al. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver[J]. Gastroenterology,2009,136(2):705-714.

[3] SAHIN H,TRAUTWEIN C,WASMUTH HE. Functional role of chemokines in liver disease models[J]. Nat Rev Gastroenterol Hepatol,2010,7(12):682-690.

[4] EHLING J,BARTNECK M,WEI X,et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis[J]. Gut,2014,63(12):1960-1971.

[5] PARKER R,WESTON CJ,MIAO Z,et al. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease[J]. Am J Physiol Gastrointest Liver Physiol,2018,314(4):g483-g493.

[6] PENG Z,XIANG J,HE Z,et al. Colonic transendoscopic enteral tubing:A novel way of transplanting fecal microbiota[J].Endosc Int Open,2016,4(6):e610-e613.

[7] SAIMAN Y,FRIEDMAN SL. The role of chemokines in acute liver injury[J]. Front Physiol,2012,3:213.

[8] WEISKIRCHEN R,TACKE F. Liver fibrosis:From pathogenesis to novel therapies[J]. Dig Dis,2016,34(4):410-422.

[9] BAECK C,WEHR A,KARLMARK KR,et al. Pharmacological inhibition of the chemokine CCL2(MCP-1)diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury[J]. Gut,2012,61(3):416-426.

[10] TSUCHIDA T,FRIEDMAN SL. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol,2017,14(7):397-411.

[11] MITCHELL C,COUTON D,COUTY JP,et al. Dual role of CCR2in the constitution and the resolution of liver fibrosis in mice[J].Am J Pathol,2009,174(5):1766-1775.

[12] KRENKEL O,PUENGEL T,GOVAERE O,et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis[J]. Hepatology,2018,67(4):1270-1283.

[13] SEKI E,de MINICIS S,INOKUCHI S,et al. CCR2 promotes hepatic fibrosis in mice[J]. Hepatology,2009,50(1):185-197.

[14] KRUGLOV EA,NATHANSON RA,NGUYEN T,et al. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts[J]. Am J Physiol Gastrointest Liver Physiol,2006,290(4):g765-g771.

[15] MARRA F,ROMANELLI RG,GIANNINI C,et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells[J]. Hepatology,1999,29(1):140-148.

[16] DING Z,ZHUO L. Attenuation of hepatic fibrosis by an imidazolium salt in thioacetamide-induced mouse model[J]. J Gastroenterol Hepatol,2013,28(1):188-201.

[17] MIURA K,YANG L,van ROOIJEN N,et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2[J]. Am J Physiol Gastrointest Liver Physiol,2012,302(11):g1310-g1321.

[18] KARLMARK KR,WEISKIRCHEN R,ZIMMERMANN HW,et al.Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis[J]. Hepatology,2009,50(1):261-274.

[19] LEE H,LEE Y,KIM J,et al. Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice[J]. Gut Microbes,2018,9(2):155-165.

[20] THAPALIYA S,WREE A,POVERO D,et al. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model[J]. Dig Dis Sci,2014,59(6):1197-1206.

[21] DONGIOVANNI P,MERONI M,BASELLI GA,et al. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease[J]. Clin Sci(Lond),2017,131(12):1301-1315.

[22] KAWANO Y,NAKAE J,WATANABE N,et al. Colonic Pro-inflammatory Macrophages Cause Insulin Resistance in an Intestinal Ccl2/Ccr2-Dependent Manner[J]. Cell Metab,2016,24(2):295-310.

[23] MULDER P,van den HOEK AM,KLEEMANN R. The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance,adipose tissue inflammation and non-alcoholic steatohepatitis[J]. PLo S One,2017,12(1):e0169740-e0169740.

[24] LI X,YAO W,YUAN Y,et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J]. Gut,2017,66(1):157-167.

[25] BARTNECK M,SCHRAMMEN PL,MCKEL D,et al. The CCR2(+)macrophage subset promotes pathogenic angiogenesis for tumor vascularization in fibrotic livers[J]. Cel Mol Gastroenterol Hepatol,2018,7(2):371-390.

[26] GLSSNER A,EISENHARDT M,KRMER B,et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-,Fas L-and NKG2D-dependent manner[J]. Lab Invest,2012,92(7):967-977.

[27] JEONG WI,PARK O,SUH YG,et al. Suppression of innate immunity(natural killer cell/interferon-γ)in the advanced stages of liver fibrosis in mice[J]. Hepatology,2011,53(4):1342-1351.

[28] van HELDEN MJ,ZAISS DM,SIJTS AJ. CCR2 defines a distinct population of NK cells and mediates their migration during influenza virus infection in mice[J]. PLo S One,2012,7(12):e52027-e52027.

[29] TENG KY,HAN J,ZHANG X,et al. Blocking the CCL2-CCR2 axis using ccl2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model[J]. Mol Cancer Ther,2017,16(2):312-322.

[30] LEFEBVRE E,MOYLE G,RESHEF R,et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis[J]. PLo S One,2016,11(6):e0158156-e0158156.

[31] KRUGER AJ,FUCHS BC,MASIA R,et al. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis[J]. Hepatol Commun,2018,2(5):529-545.

[32] THOMPSON M,SAAG M,DEJESUS E,et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus[J]. AIDS,2016,30(6):869-878.

[33] FRIEDMAN SL,RATZIU V,HARRISON SA,et al. A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology,2018,67(5):1754-1767.

施引文献

资源附件(0)

访问统计